Key takeaways
Lamivudine (Epivir) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are both medications used to treat human immunodeficiency virus (HIV) infections. However, they belong to different medication classes and have distinct characteristics. Lamivudine (Epivir) is a nucleoside reverse transcriptase inhibitor (NRTI) that is also used to treat hepatitis B virus (HBV), while Genvoya is a combination antiretroviral therapy (ART) that includes two NRTIs, an integrase strand transfer inhibitor (INSTI), and a booster. Lamivudine (Epivir) is available in both brand and generic forms and can be taken once or twice daily, whereas Genvoya is taken as a single tablet once daily with food and is not available as a generic. Common side effects of lamivudine (Epivir) include headache, nausea, and fatigue, while Genvoya may cause nausea and diarrhea. Genvoya has more potential drug interactions, such as with certain seizure medications and blood thinners, compared to lamivudine (Epivir), which has fewer interactions. Additionally, Genvoya is not recommended for use during pregnancy, while lamivudine (Epivir) can be considered safe during pregnancy with proper medical guidance.
